M6223

DRUG2 trials

Sponsors

EMD Serono Research & Development Institute, Inc.

Conditions

Locally Advanced or Metastatic Urothelial CarcinomaMetastatic Solid Tumors

Phase 1

First in Human Study of M6223

CompletedNCT04457778

EMD Serono Research & Development Institute, Inc.Metastatic Solid Tumors

Start: 2020-07-10End: 2023-06-23Updated: 2023-12-08

Phase 2

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Active, not recruitingNCT05327530

EMD Serono Research & Development Institute, Inc.Locally Advanced or Metastatic Urothelial Carcinoma

Start: 2022-08-17End: 2026-06-25Updated: 2026-01-26

Related Papers

Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.

Journal of Clinical Oncology2025-05-282 citations

TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial

Journal for ImmunoTherapy of Cancer2025-02-015 citations

Abstract CT184: First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors

Cancer Research2024-04-051 citations

The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma

Future Oncology2023-09-0612 citations

665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma

Regular and Young Investigator Award Abstracts2022-11-014 citations

432 Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity

Regular and Young Investigator Award Abstracts2022-11-012 citations

497 Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223

Regular and Young Investigator Award Abstracts2022-11-011 citations

Abstract 593: Anti-tumor immunity and efficacy of combination treatment of M6223 and bintrafusp alfa versus the combination of M6223 and anti-PD-L1 in preclinical tumor models

Cancer Research2022-06-151 citations

326 The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action

Regular and Young Investigator Award Abstracts2021-11-012 citations

530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations